For Daniil Boiko and Andrei Tyrin, the thought for Onepot AI got here from the identical frustration.
“The greatest concepts in drug discovery had been typically blocked not by biology, however by synthesis,” Boiko informed TechCrunch. Synthesis is the creation of latest molecules through the use of chemical reactions. It’s like a recipe or Lego items, the place small items, substances, molecules, come collectively to kind a wider puzzle image, a meals dish, a bigger molecule.
As one would possibly anticipate, it’s fairly arduous to create these small molecules that go on to construct larger ones.
For Boiko, a Ph.D. candidate finding out machine studying in chemistry at Carnegie Mellon (he obtained his bachelor’s and grasp’s in natural chemistry from a college in Russia), that meant realizing that drug hunters — the scientists who oversee drug discovery and improvement — had been skipping promising concepts simply because the chemical molecules to create the medicine appeared too arduous to make.
“The compounds by no means even received an opportunity to be examined,” Boiko informed TechCrunch.
For Tyrin (who obtained his bachelor’s in laptop science at MIT), his time working on drug discovery computational pipelines made him understand how behind the world of drug discovery was. “The fashions may generate concepts in hours, however it may take months for the lab to catch up,” he informed TechCrunch.
“We each noticed that the world was throwing cash into molecular design and nearly ignoring the more durable downside of really making the molecules,” Boiko stated. However there was a geopolitical angle too, he continued, world provide chains have gotten susceptible, and the U.S. is coming into a commerce warfare and modern competitors, as soon as once more, with China.
Techcrunch occasion
San Francisco
|
October 13-15, 2026
“It was clear,” Boiko stated. “Small molecule synthesis wanted to be rebuilt from the floor up in the United States.”
Boiko and Tyrin got here collectively to create Onepot, an organization that’s house to the small-molecule synthesis lab POT-1. In addition they constructed Phil, an AI natural chemist, to assist run experimental evaluation to extend the course of of compound synthesis for their early industrial companions. These companions are biotech and pharma firms which might be at present making an attempt out their expertise.
On Wednesday, the firm got here out of stealth with $13 million of funding, together with pre-seed cash, and a seed spherical led by Fifty Years.
“At the moment, pharma and biotech firms both construct total groups of chemists in-house or work with contract analysis organizations abroad,” Tryin stated of the course of for molecular synthesis. Human chemists can spend months of analysis to create even a single compound, at a value of 1000’s of {dollars}.
It entails a number of trial and error — finding out numerous compounds, gathering knowledge on organic exercise, how the drug strikes by way of the physique, toxicology reviews, and developing with what to experiment with subsequent. “The foremost limiting issue right here is just not testing these compounds, however making them in the first place,” Tyrin continued. “We purpose to compress this all the way down to days.”
Tyrin stated the product is fairly simple. Onepot has a listing of molecules it will probably make. Shoppers select which compounds it need and then Onepot’s expertise will synthesize the molecules and then ship them to the buyer so the buyer can use them in their very own experiments. (They ship bodily merchandise both as dry compounds of options in plates or vials).
The backend of the product is the place Boiko and Tyrin have enjoyable, dissecting the issues of chemical synthesis to search out out which combos of molecules work collectively. They constructed a lab the place they’re letting LLM brokers entry these so-called molecule recipes for coaching so the brokers can even discover out what works and doesn’t in compound constructing.
“When executing experiments in the lab, we seize each single element that goes into the course of,” Tyrin stated — meaning tracing temperature and, basically, the substances that had been added to a combination to create compounds. “No data is misplaced, which makes experiences reproducible even when somebody decides to run them in ten years from now.”
This additionally means their brokers generate hypotheses from real-world experiments reasonably than literature knowledge, typically mined from the web.
Boiko referred to as the fundraising course of “hectic,” and stated they met their lead investor by way of an intro. “What was alleged to be a brief assembly become a multi-hour whiteboard session about industrializing synthesis,” Boiko stated. Others in the spherical embody Khosla Ventures, Speedinvest, OpenAI co-founder Wojciech Zaremba and Google’s Chief Scientist Jeff Dean.
The recent capital can be used to construct a second lab in San Francisco so the staff can tackle extra clients. It would additionally increase the staff and its compound discovery engine. On the service facet, Boiko and Tyrin take a look at WuXi AppTec and Enamine as opponents.
General, Boiko and Tyrin hope to make drug discovery at the least two instances sooner and hopefully change the notion of what’s potential after one faucets into the “bizarre” chemistry that scientists as soon as thought was off limits.
“You’re not simply dashing up drug discovery, you’re increasing the design area for what medicine and supplies might be,” Boiko stated. “That drug that we haven’t found but, is likely to be out there, ready for us to search out it.”
